drug
corticotropin
Marketedupdated 5mo agoby Cerium Pharmaceuticals Inc
Approvedcommunity read0 votes
indications
investigational
Rheumatoid ArthritisPsoriasisLupus
all catalysts(0)
nothing on the calendar yet
Trials studying corticotropin
- phase4Treatment of CNS Sarcoidosis With H.P. Acthar Gel
- phase4Use of Acthar in Rheumatoid Arthritis (RA) Related Flares
- phase4Efficacy and Safety of H.P. Acthar Gel for the Treatment of Refractory Cutaneous Manifestations of Dermatomyositis
- phase3The Effects of Acthar on Synovial Inflammation in Rheumatoid Arthritis
- N/AOcular Sarcoidosis Open Label Trial of ACTHAR Gel
- N/AACTH Gel Therapy in Rheumatoid Arthritis
Patent cliff
source: FDA Orange Bookfirst barrier falls
Jul 18, 2041
~14.8 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (9)
- Oct 27, 2043method-of-use (U-3926)US 11975047
- Oct 27, 2043method-of-use (U-3915)US 12102662
- Oct 27, 2043method-of-use (U-3916)US 12102662
- Oct 27, 2043method-of-use (U-3911)US 12233105
- Oct 27, 2043formulationUS 12324787
- Oct 27, 2043formulationUS 12440542
- Jul 18, 2041method-of-use (U-3688)US 11752199
- Jul 18, 2041method-of-use (U-3688)US 11752199
- Jul 18, 2041method-of-use (U-3688)US 11752199
News(1)
- Why Roche is 'really excited' about a UCN2 analog for obesity after seeing preclinical dataRoche has decided to pay $190 million upfront for an unusual obesity mechanism after viewing preclinical data that “clearly suggests” the modality can reduce weight while preserving lean muscle, Fi…fiercebiotech · 1mo ago
Data sources
last refreshed 53m ago
Found something off?
comments(0)
5-min edit window · permanent after that